Comparative gene expression analysis in the skeletal muscles of dysferlin-defcient SJL/J and A/J mice

Journal of Toxicologic Pathology

Volumn 24, Issue 1, 2011, Pages 49-62

  Kobayashi, Kinji ^a   Izawa, Takeshi ^a   Kuwamura, Mitsuru ^a   Yamate, Jyoji ^a  

^a Osaka City University   (Japan)

Author keywords

A J mouse; Decay accelerating factor; Dysferlin; Heat shock protein; Heme oxygenase 1; SJL J mouse

Indexed keywords

CALVASCULIN; DECAY ACCELERATING FACTOR; DYSFERLIN; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; UNCOUPLING PROTEIN 2;

A J MOUSE; ABDOMINAL WALL MUSCULATURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DYSFERLINOPATHY; GENE EXPRESSION PROFILING; GENE LOCATION; HISTOPATHOLOGY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RECTUS FEMORIS MUSCLE; STRAIN DIFFERENCE; SWISS JAMES LAMBERT MOUSE; TISSUE DISTRIBUTION; UPREGULATION;

EID: 79955385633     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.24.49     Document Type: Article

References (47)

1. Cohn RD, and Campbell KP. Molecular basis of muscular dystrophies. Muscle Nerve. 23: 1456-1471. 2000.[Medline] [CrossRef]
2. Han R, Bansal D, Miyake K, Muniz VP, Weiss RM, McNeil PL, and Campbell KP. Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J Clin Invest. 117: 1805-1813. 2007.[Medline] [CrossRef]
3. Glover L, and Brown RH. Dysferlin in membrane trafficking and patch repair. Traffc. 8: 785-794. 2007.[Med-line] [CrossRef]
4. Bittner RE, Anderson LV, Burkhardt E, Bashir R, Vafadaki E, Ivanova S, Raffelsberger T, Maerk I, Hoger H, Jung M, Karbasiyan M, Storch M, Lassmann H, Moss JA, Davison K, Harrison R, Bushby KM, and Reis A. Dysferlin deletion in SJL mice (SJL-Dysf) defnes a natural model for limb girdle muscular dystrophy 2B. Nat Genet. 23: 141-142. 1999.[Medline] [CrossRef]
5. Ho M, Post CM, Donahue LR, Lidov HG, Bronson RT, Goolsby H, Watkins SC, Cox GA, and Brown RH. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin defciency. Hum Mol Genet. 13: 1999-2010. 2004.[Medline] [CrossRef]
6. Vafadaki E, Reis A, Keers S, Harrison R, Anderson LV, Raffelsberger T, Ivanova S, Hoger H, Bittner RE, Bushby K, and Bashir R. Cloning of the mouse dysferlin gene and genomic characterization of the SJL-Dysf mutation. Neuro-report. 12: 625-629. 2001.[Medline] [CrossRef]
7. 2+-binding domain. J Biol Chem. 273: 15879-15882. 1998.[Medline] [CrossRef]
8. Kobayashi K, Izawa T, Kuwamura M, and Yamate J. The distribution and characterization of skeletal muscle lesions in dysferlin-defcient SJL and A/J mice. Exp Toxicol Pathol. 62: 509-517. 2010.[Medline] [CrossRef]
9. Campanaro S, Romualdi C, Fanin M, Celegato B, Pacchioni B, Trevisan S, Laveder P, De Pittà C, Pegoraro E, Hayashi YK, Valle G, Angelini C, and Lanfranchi G. Gene expression profling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet. 11: 3283-3298. 2002.[Med-line] [CrossRef]
10. von der Hagen M, Laval SH, Cree LM, Haldane F, Pocock M, Wappler I, Peters H, Reitsamer HA, Hoger H, Wiedner M, Oberndorfer F, Anderson LV, Straub V, Bittner RE, and Bushby KM. The differential gene expression profiles of proximal and distal muscle groups are altered in pre-path-ological dysferlin-defcient mice. Neuromuscul Disord. 15: 863-877. 2005.[Medline] [CrossRef]
11. Suzuki N, Aoki M, Hinuma Y, Takahashi T, Onodera Y, Ish-igaki A, Kato M, Warita H, Tateyama M, and Itoyama Y. Expression profling with progression of dystrophic change in dysferlin-defcient mice (SJL). Neurosci Res. 52: 47-60. 2005.[Medline] [CrossRef]
12. Turk R, Sterrenburg E, van der Wees CG, de Meijer EJ, de Menezes RX, Groh S, Campbell KP, Noguchi S, van Om-men GJ, den Dunnen JT, and ťHoen PA. Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J. 20: 127-129. 2006.[Medline]
13. Weller AH, Magliato SA, Bell KP, and Rosenberg NL. Spontaneous myopathy in the SJL/J mouse: pathology and strength loss. Muscle Nerve. 20: 72-82. 1997.[Medline] [CrossRef]
14. Chadt A, Leicht K, Deshmukh A, Jiang LQ, Scherneck S, Bernhardt U, Dreja T, Vogel H, Schmolz K, Kluge R, Zier-ath JR, Hultschig C, Hoeben RC, Schürmann A, Joost HG, and Al-Hasani H. Tbc1d1 mutation in lean mouse strain confers leanness and protects from diet-induced obesity. Nat Genet. 40: 1354-1359. 2008.[Medline] [CrossRef]
15. Samec S, Seydoux J, and Dulloo AG. Skeletal muscle UCP3 and UCP2 gene expression in response to inhibition of free fatty acid fux through mitochondrial beta-oxidation. Pfugers Arch. 438: 452-457. 1999.[Medline] [CrossRef]
16. Bonen A. PGC-1alpha-induced improvements in skeletal muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab. 34: 307-314. 2009.[Medline] [CrossRef]
17. Carnac G, Vernus B, and Bonnieu A. Myostatin in the pathophysiology of skeletal muscle. Curr Genomics. 8: 415-422. 2007.[Medline] [CrossRef]
18. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, and Patel K. Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogen-esis. Dev Biol. 270: 19-30. 2004.[Medline] [CrossRef]
19. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, and Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 39: 283-296. 2009.[Medline] [CrossRef]
20. Fujita E, Kouroku Y, Isoai A, Kumagai H, Misutani A, Matsuda C, Hayashi YK, and Momoi T. Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Hum Mol Genet. 16: 618-629. 2007.[Medline] [CrossRef]
21. Maglara AA, Vasilaki A, Jackson MJ, and McArdle A. Damage to developing mouse skeletal muscle myotubes in culture: protective effect of heat shock proteins. J Physiol. 548: 837-846. 2003.[Medline] [CrossRef]
22. Kostek CA, Dominov JA, and Miller JB. Upregulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-defcient SJL/J mice. Am J Pathol. 160: 833-839. 2002.[Medline]
23. Zhang Y, Baig E, and Williams DB. Functions of ERp57 in the folding and assembly of major histocompatibility complex class I molecules. J Biol Chem. 281: 14622-14631. 2006.[Medline] [CrossRef]
24. Yoshida H, Matsui T, Hosokawa N, Kaufman RJ, Nagata K, and Mori K. A time-dependent phase shift in the mammalian unfolded protein response. Dev Cell. 4: 265-271. 2003.[Medline] [CrossRef]
25. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, Fortuni S, Straino S, Sampaolesi M, di Pado-va M, Illi B, Gallinari P, Steinkühler C, Capogrossi MC, Sartorelli V, Bottinelli R, Gaetano C, and Puri PL. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 12: 1147-1150. 2006.[Medline] [CrossRef]
26. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, Perrotta C, Monopoli A, Sanvito F, Botti-nelli R, Ongini E, Cossu G, and Clementi E. Nitric oxide release combined with nonsteroidal antiinfammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA. 104: 264-269. 2007.[Medline] [CrossRef]
27. Rando TA, Disatnik MH, Yu Y, and Franco A. Muscle cells from mdx mice have an increased susceptibility to oxida-tive stress. Neuromuscul Disord. 8: 14-21. 1998.[Medline] [CrossRef]
28. Soares MP, and Bach FH. Heme oxygenase-1: from biology to therapeutic potential. Trends Mol Med. 15: 50-58. 2009.[Medline] [CrossRef]
29. Arnér ES, and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 267: 6102-6109. 2000.[Medline] [CrossRef]
30. Wenzel K, Zabojszcza J, Carl M, Taubert S, Lass A, Harris CL, Ho M, Schulz H, Hummel O, Hubner N, Osterziel KJ, and Spuler S. Increased susceptibility to complement attack due to downregulation of decay-accelerating factor/CD55 in dysferlin-defcient muscular dystrophy. J Immunol. 175: 6219-6225. 2005.[Medline]
31. Pfaff MW. A new mathematical model for relative quanti-fcation in real-time RT-PCR. Nucleic Acids Res. 29: e45. 2001.[Medline] [CrossRef]
32. Pfaff MW, Horgan GW, and Dempfe L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30: e36. 2002.[Medline] [Cross-Ref]
33. Bodyak N, Rigor DL, Chen YS, Han Y, Bisping E, Pu WT, and Kang PM. Uncoupling protein 2 modulates cell viability in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol. 293: H829-H835. 2007.[Medline] [CrossRef]
34. Li ZH, Dulyaninova NG, House R P, Almo SC, and Bresnick AR. S100A4 regulates macrophage chemotaxis. Mol Biol Cell. 21: 2598-2610. 2010.[Medline] [CrossRef]
35. Lund TC, Grange RW, and Lowe DA. Telomere shortening in diaphragm and tibialis anterior muscles of aged mdx mice. Muscle Nerve. 36: 387-390. 2007.[Medline] [Cross-Ref]
36. Aguennouz M, Vita GL, Messina S, Cama A, Lanzano N, Ciranni A, Rodolico C, di Giorgio RM, and Vita G. Telo-mere shortening is associated to TRF1 and PARP1 overex-pression in Duchenne muscular dystrophy. Neurobiol Aging. 2010 (in press). [Medline] [CrossRef]
37. Langin D. The role of uncoupling protein 2 in the development of type 2 diabetes. Drugs Today (Barc). 39: 287-295. 2003.[Medline] [CrossRef]
38. Roach WG, Chavez JA, Mîinea CP, and Lienhard GE. Substrate specifcity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1. Biochem J. 15(403): 353-358. 2007.[Medline]
39. Islam T, McConnell R, Gauderman WJ, Avol E, Peters JM, and Gilliland FD. Ozone, oxidant defense genes, and risk of asthma during adolescence. Am J Respir Crit Care Med. 177: 388-395. 2008.[Medline] [CrossRef]
40. Jorquera G, Juretić N, Jaimovich E, and Riveros N. Membrane depolarization induces calcium-dependentupregu-lation of Hsp70 and Hmox-1 in skeletal muscle cells. Am J Physiol Cell Physiol. 297: C581-C590. 2009.[Medline] [CrossRef]
41. Silomon M, Bauer I, Bauer M, Nolting J, Paxian M, and Rensing H. Induction of heme oxygenase-1 and heat shock protein 70 in rat hepatocytes: the role of calcium signaling. Cell Mol Biol Lett. 12: 25-38. 2007.[Medline] [CrossRef]
42. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, and Campbell K P. Defective membrane repair in dysferlin-defcient muscular dystrophy. Nature. 423: 168-172. 2003.[Medline] [CrossRef]
43. O'Neill DE, and Noble EG. Constitutive expression of in-ducible Hsp70 is linked to natural shifts in skeletal muscle phenotype. Acta Physiol Scand. 181: 35-41. 2004.[Med-line] [CrossRef]
44. Krajacic P, Hermanowski J, Lozynska O, Khurana TS, and Lamitina T. The C. elegans Dysferlin homolog fer-1 is expressed in muscle and fer-1 mutations initiate altered gene expression of muscle enriched genes. Physiol Genomics. 40: 8-14. 2009.[Medline] [CrossRef]
45. Lynch DM, and Kay PH. Studies on the polymorphism of the fifth component of complement in laboratory mice. Exp Clin Immunogenet. 12: 253-620. 1995.[Medline]
46. Rhodes JC, Wicker LS, and Urba WJ. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun. 29: 494-499. 1980.[Medline]
47. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, Morandi L, Mora M, Cornelio F, and Man-tegazza R. Muscle infammation and MHC class I upregulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol. 142: 130-136. 2003.[Medline] [CrossRef]